Banerjee Subhashis sold $5K of ARTV

Banerjee Subhashis (Chief Medical Officer) sold 1,110 shares of Artiva Biotherapeutics, Inc. (ARTV) at $4.18 on 2026-11-02.

Original reporting
SEC EDGAR · Banerjee Subhashis
Published Nov 3, 2026, 9:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 9:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ARTV
Neutral
high confidence
Mentioned
$ARTV
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARTVNeutralLow
01

Why it matters

The disclosed sale is modest and unlikely to move the stock significantly, but it provides transparency for investors.

02

Market read

A small insider sale that offers limited trading insight; most traders will likely ignore.

03

What to watch

No pre‑arranged 10b5‑1 plan; the CMO may be reallocating capital, which could be neutral or positive.

Relevance 3/10Novelty 3/10Timing: today

Background

Form 4 filing discloses insider transactions required by the SEC.

Company-level read

Ticker impact

$ARTVNeutralHigh confidence
Context

Chief Medical Officer Banerjee Subhashis sold 1,110 shares for $4,641 on 2026-11-02.

Expected impact

likely pressure as the market prices in the insider sell

Evidence & confidence

The sale is small relative to holdings (168,738 shares) and typical for a 10b5‑1 plan, but any CMO sell can be viewed negatively.

Market effects

Minimal impact on biotech sector; similar insider sales are routine.

None

Low

Counterpoint

The sale could be a routine liquidity event and not indicative of negative fundamentals.

Key entities

  • Artiva Biotherapeutics, Inc.

    US‑listed biotech company (ticker ARTV).

  • Banerjee Subhashis

    Chief Medical Officer of Artiva Biotherapeutics.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Low

Artiva Ends AlloNK Autoimmune Cell Therapy After Two Trial Deaths, One Unexplained, and Cuts 94% of Staff

Artiva Biotherapeutics halted its AlloNK cell therapy trial for autoimmune diseases after two participant deaths, one linked to chemotherapy. The company will cut 94% of its staff and explore strategic options, including a sale or dissolution. AlloNK was tested with rituximab in rheumatoid arthritis and other autoimmune diseases. Artiva reported $319.1 million in cash as of September 30.

$ARTVMed

Jefferies downgrades Artiva Biotherapeutics stock rating to hold

Jefferies downgraded Artiva Biotherapeutics (ARTV) to Hold with a $4.00 price target after the company discontinued its AlloNK program due to safety concerns and lack of long-term efficacy in rheumatoid arthritis patients. The stock is down 31% over the past week. The company is cutting 94% of staff and exploring strategic alternatives, though it has strong short-term liquidity. Analysts have mixed views, with some maintaining bullish ratings and high price targets.

MedAI 8/10

Patients Deaths and Data Shortfall Spell the End for Cell Therapy Biotech Artiva

Artiva Biotherapeutics is halting its lead cell therapy program, AlloNK, after two patient fatalities in a mid-stage trial and updated clinical data raising concerns about its efficacy. The company will lay off 94% of its staff and has $319.1 million in cash. Analysts note potential implications for Nkarta and Fate Therapeutics, with Nkarta's upcoming data presentation under scrutiny.